Re-boost immunizations with the peptide-based therapeutic HIV vaccine, Vacc-4x, restores geometric mean viral load set-point during treatment interruption
Fig 7
The proportion of per protocol participants showing positive T-cell proliferation assay responses during the 2012/1 study at week (wk)1 and wk52 in the 2007/1 study.
For participants with values at wk0 in the 2012/1 and wk1 in the 2007/1 study, the difference in the proportion of participants with positive assay responses for the CD4 T-cell population was statistically significant (-0.462; CI: -0.733, -0.191, p = 0.031 n = 13), but not for the proportion of participants with CD8 T-cell proliferation responses (-0.200, CI: -0.420, 0.002, p = 0.250, n = 15). The two-sided p-value was derived from exact version of McNemar’s test. The 95% CI may not be valid as analysis is based on a small sample of data. The sample size was too small for a comparison of T-cell proliferation assay responses between wk28 in the 2012/1 study and wk52 in the 2007/1 study in participants that had data for both time points (CD4 n = 7; CD8 n = 7). *Participants contributing data to the p-value.